Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-Current Deffered Revenue: 2022-2024

Historic Non-Current Deffered Revenue for Kiniksa Pharmaceuticals International (KNSA) over the last 3 years, with Dec 2024 value amounting to $31.8 million.

  • Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue rose 169.33% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year increase of 169.33%. This contributed to the annual value of $31.8 million for FY2024, which is 166.11% up from last year.
  • As of FY2024, Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue stood at $31.8 million, which was up 166.11% from $12.0 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue's 5-year high stood at $31.8 million during FY2024, with a 5-year trough of $12.0 million in FY2023.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Non-Current Deffered Revenue value was $12.0 million (recorded in 2022), while the average stood at $18.6 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue fell by 0.38% in 2023, and later skyrocketed by 166.11% in 2024.
  • Yearly analysis of 3 years shows Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue stood at $12.0 million in 2022, then dropped by 0.38% to $12.0 million in 2023, then skyrocketed by 166.11% to $31.8 million in 2024.